KR20220044435A - 인디고 및/또는 인디고 유도체를 포함하는 조성물 및 이의 사용 방법 - Google Patents

인디고 및/또는 인디고 유도체를 포함하는 조성물 및 이의 사용 방법 Download PDF

Info

Publication number
KR20220044435A
KR20220044435A KR1020217039676A KR20217039676A KR20220044435A KR 20220044435 A KR20220044435 A KR 20220044435A KR 1020217039676 A KR1020217039676 A KR 1020217039676A KR 20217039676 A KR20217039676 A KR 20217039676A KR 20220044435 A KR20220044435 A KR 20220044435A
Authority
KR
South Korea
Prior art keywords
indirubin
indigo
dosage form
dispersion
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020217039676A
Other languages
English (en)
Korean (ko)
Inventor
매튜 데이비슨
줄리 사이키
요한 안드레아손
마이클 데이비드 파베로
매튜 벤자민 그린
Original Assignee
아조라 테라퓨틱스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아조라 테라퓨틱스 인코포레이티드 filed Critical 아조라 테라퓨틱스 인코포레이티드
Publication of KR20220044435A publication Critical patent/KR20220044435A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217039676A 2019-05-03 2020-05-01 인디고 및/또는 인디고 유도체를 포함하는 조성물 및 이의 사용 방법 Withdrawn KR20220044435A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962843184P 2019-05-03 2019-05-03
US62/843,184 2019-05-03
PCT/US2020/031174 WO2020227151A1 (en) 2019-05-03 2020-05-01 Compositions comprising indigo and/or an indigo derivative and methods of use thereof

Publications (1)

Publication Number Publication Date
KR20220044435A true KR20220044435A (ko) 2022-04-08

Family

ID=70775588

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217039676A Withdrawn KR20220044435A (ko) 2019-05-03 2020-05-01 인디고 및/또는 인디고 유도체를 포함하는 조성물 및 이의 사용 방법

Country Status (10)

Country Link
US (3) US20200345645A1 (https=)
EP (1) EP3962458A1 (https=)
JP (1) JP2022531012A (https=)
KR (1) KR20220044435A (https=)
CN (1) CN114340600A (https=)
AU (1) AU2020269379A1 (https=)
CA (1) CA3136081A1 (https=)
MX (1) MX2021013386A (https=)
TW (1) TW202106296A (https=)
WO (1) WO2020227151A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023170714A1 (en) * 2022-03-10 2023-09-14 Joy Vadakkan Thomas A topical herbal composition for fungal infection, scaling, foot cracking, eczema and dry skin diseases

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021174024A1 (en) 2020-02-28 2021-09-02 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
KR20240152820A (ko) 2021-11-30 2024-10-22 엔도퀘스트 로보틱스 인코포레이티드 로봇 제어 의료 기기용 힘 전달 시스템
JP2025532421A (ja) * 2022-10-10 2025-09-29 上海澤徳曼医薬科技有限公司 潰瘍を予防及び又は治療するためのスチルベン誘導体の使用
WO2025008784A1 (en) * 2023-07-04 2025-01-09 Glenmark Life Sciences Limited Solid dispersions of tapinarof and a process for the preparation thereof
CN121337758A (zh) * 2025-11-26 2026-01-16 河北省中医院(河北中医药大学第一附属医院、河北省青少年儿童脊柱侧弯防控中心) 一种可降解的肠道药物靶向释放胶囊及制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US7582670B2 (en) * 2001-12-13 2009-09-01 Natrogen Therapeutics, Inc. Methods of treating an inflammatory-related disease
JP2013103899A (ja) * 2011-11-11 2013-05-30 Fuji Chem Ind Co Ltd 難溶性薬物の新規な固体分散体
EP2863897B1 (en) * 2012-06-21 2019-06-19 Phosphorex Inc. Nanoparticles of indirubin, derivatives thereof and methods of making and using same
TWI615157B (zh) * 2013-02-06 2018-02-21 大塚製藥股份有限公司 包括不定形西洛他唑的固體分散劑
JP2017500343A (ja) * 2013-12-20 2017-01-05 フォスフォレックス，インコーポレーテッド インジルビン固体分散体組成物
BR112017021190B1 (pt) 2015-04-09 2021-12-21 Galderma Sa. Uso de uma composição farmacêutica que compreende um extrato de indigo naturalis
BR112018071370A2 (pt) * 2016-04-19 2019-02-05 Ferring Bv composições farmacêuticas orais de mesalazina
JP7325753B2 (ja) * 2018-01-18 2023-08-15 慶應義塾 潰瘍性大腸炎治療カプセル剤

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023170714A1 (en) * 2022-03-10 2023-09-14 Joy Vadakkan Thomas A topical herbal composition for fungal infection, scaling, foot cracking, eczema and dry skin diseases

Also Published As

Publication number Publication date
TW202106296A (zh) 2021-02-16
US20200345645A1 (en) 2020-11-05
CA3136081A1 (en) 2020-11-12
US20220249382A1 (en) 2022-08-11
CN114340600A (zh) 2022-04-12
EP3962458A1 (en) 2022-03-09
AU2020269379A1 (en) 2021-12-02
MX2021013386A (es) 2022-03-22
WO2020227151A1 (en) 2020-11-12
US20250255820A1 (en) 2025-08-14
JP2022531012A (ja) 2022-07-05

Similar Documents

Publication Publication Date Title
US20250255820A1 (en) Compositions comprising indigo and/or an indigo derivative and methods of use thereof
US12318385B2 (en) Pharmaceutical composition comprising PARP inhibitors
BRPI0608853B1 (pt) composições farmacêuticas e processo para a fabricação de microgrânulos de rifaximina gastrorresistentes
US20090111788A1 (en) Antibiotic compositions of modified release and process of production thereof
JPH02104A (ja) 薬物放出速度調節型製剤
CN114727948A (zh) Tyk2抑制剂的延长释放剂型
AU2007242405A1 (en) Novel low dose pharmaceutical compositions comprising nimesulide, preparation and use thereof
US12403131B2 (en) Afabicin formulation, method for making the same and uses thereof
US20100204333A1 (en) Novel Pharmaceutical Modified Release Dosage Form Cyclooxygenase Enzyme Inhibitor
US20200345691A1 (en) Compositions comprising indigo and/or an indigo derivative and methods of use thereof
US20210369624A1 (en) Solid oral dosage form having excellent dissolution properties
US20110262540A1 (en) Solid Pharmaceutical Composition Comprising Exemestane
BRPI0810697A2 (pt) formulações orais de liberação controlada de compostos de modulação de canal de íon e métodos relacionados à prevenção de arritmia
EP4054613A1 (en) Gut-protective compositions comprising boswellic acid
KR0184350B1 (ko) 오메프라졸 구강점막 부착 정제 조성물
US20110287091A1 (en) Chronotherapeutic pharmaceutical composition
HK40063531B (en) Afabicin formulation, method for making the same
HK40063531A (en) Afabicin formulation, method for making the same
Asif Design and Characterization of Colon Targeted Nimesulide Double Coated Tablets for the Prophylaxis of Colon Cancer

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203